Thrombotic microangiopathy in oncology – a review
Open Access
- 1 July 2021
- journal article
- review article
- Published by Elsevier in Translational Oncology
- Vol. 14 (7) , 101081
Abstract
No abstract availableKeywords
This publication has 139 references indexed in Scilit:
- Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host Disease ProphylaxisTransplantation and Cellular Therapy, 2013
- The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolateHaematologica, 2012
- Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant–associated thrombotic microangiopathy?Transfusion, 2012
- Thrombotic Microangiopathy with Targeted Cancer AgentsClinical Cancer Research, 2011
- Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- Chronic Kidney Disease, Thrombotic Microangiopathy, and Hypertension Following T Cell-Depleted Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2010
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Renal Thrombotic Microangiopathy after Hematopoietic Cell TransplantClinical Journal of the American Society of Nephrology, 2009
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Defibrotide Protects Endothelial Cells, but not L929 Tumour Cells, from Tumour Necrosis Factor-α-mediated CytotoxicityJournal of Pharmacy and Pharmacology, 1995